KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $2.4 million.

  • Xenon Pharmaceuticals' Cash from Financing Activities changed N/A to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.7 million, marking a year-over-year decrease of 9515.27%. This contributed to the annual value of $12.1 million for FY2024, which is 9656.88% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $2.4 million for Q3 2025.
  • Xenon Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $324.0 million during Q4 2023, with a 5-year trough of $6000.0 in Q4 2022.
  • Moreover, its 5-year median value for Cash from Financing Activities was $4.8 million (2021), whereas its average is $82.0 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Cash from Financing Activities crashed by 9999.81% in 2022, and later surged by 540013333.33% in 2023.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Cash from Financing Activities stood at $324.0 million in 2021, then plummeted by 100.0% to $6000.0 in 2022, then soared by 5400133.33% to $324.0 million in 2023, then crashed by 96.26% to $12.1 million in 2024, then plummeted by 80.54% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $65000.0 for Q2 2025, and $1.2 million during Q1 2025.